Cargando…

Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer

Oligometastatic prostate cancer (OMPC) has been proposed as an intermediary state between localised disease and widespread metastases, with varying definitions including 1, 3, or ≤5 visceral or bone metastasis. Traditional definitions of OMPC are based on staging with conventional imaging, such as c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alberto, Matthew, Yim, Arthur, Papa, Nathan, Siva, Shankar, Ischia, Joseph, Touijer, Karim, Eastham, James A., Bolton, Damien, Perera, Marlon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9433573/ https://www.ncbi.nlm.nih.gov/pubmed/36059632 http://dx.doi.org/10.3389/fonc.2022.929444

Ejemplares similares

Cribriform pattern disease over‐represented in pelvic lymph node metastases identified on (68)GA PSMA‐PET/CT
por: Bolton, Damien, et al.
Publicado: (2022)

Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET
por: Sabbagh, Ali, et al.
Publicado: (2022)

Role of surgery in oligometastatic prostate cancer
por: Jenjitranant, Pocharapong, et al.
Publicado: (2019)

Trends in percutaneous renal biopsy: The evolving diagnostic pathway for the small renal mass
por: Perera, Marlon, et al.
Publicado: (2018)

Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer
por: Henkenberens, Christoph, et al.
Publicado: (2021)

Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer
por: Mohan, Riche, et al.
Publicado: (2023)

Defining Oligometastatic Disease in the New Era of PSMA-PET Imaging for Primary Staging of Prostate Cancer
por: Galgano, Samuel J., et al.
Publicado: (2022)

68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer
por: Kalinauskaite, Goda, et al.
Publicado: (2020)

The Role of Ga-68 PSMA PET/CT Scan on Differentiating of Oligometastatic and High Risk Prostate Cancer
por: Erdoğan, Mehmet, et al.
Publicado: (2020)

Neurologically asymptomatic cerebral oligometastatic prostate carcinoma metastasis identified on [Ga]Ga-THP-PSMA PET/CT
por: Ross, M. I., et al.
Publicado: (2020)

Zinc Preconditioning Provides Cytoprotection following Iodinated Contrast Media Exposure in In Vitro Models
por: Perera, Marlon, et al.
Publicado: (2021)

Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
por: Plichta, Kristin A., et al.
Publicado: (2021)

Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy: Extended or Not. The Referee Point of View
por: Perera, Marlon, et al.
Publicado: (2022)

Correction to: Neurologically asymptomatic cerebral oligometastatic prostate carcinoma metastasis identified on [Ga]Ga-THP-PSMA PET/CT
por: Ross, M. I., et al.
Publicado: (2020)

Can pelvic node dissection at radical prostatectomy influence the nodal recurrence at salvage lymphadenectomy for prostate cancer?
por: Sivaraman, Arjun, et al.
Publicado: (2018)

Social determinants of health: does socioeconomic status affect access to staging imaging for men with prostate cancer
por: Kelly, Brian D., et al.
Publicado: (2022)

Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial
por: Privé, Bastiaan M., et al.
Publicado: (2020)

PSMA-PET Detection of Unusual Metastases in Castrate-Sensitive Prostate Carcinoma
por: Harris, Nathanial, et al.
Publicado: (2023)

Oligometastatic prostate cancer: Metastases-directed therapy?
por: Van Poppel, Hein, et al.
Publicado: (2016)

Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma
por: Udovicich, Cristian, et al.
Publicado: (2022)

Comparison of MRI, PET, and 18F-choline PET/MRI in patients with oligometastatic recurrent prostate cancer
por: Evangelista, Laura, et al.
Publicado: (2021)

PSMA PET-CT Imaging Predicts Treatment Progression in Men with Biochemically Recurrent Prostate Cancer—A Prospective Study of Men with 3 Year Follow Up
por: Ong, Sean, et al.
Publicado: (2022)

PSMA PET/CT to evaluate response to SBRT for prostate cancer bone metastases
por: Sadetski, Igor, et al.
Publicado: (2021)

PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer
por: Deijen, Charlotte L., et al.
Publicado: (2021)

Mesorectal Lymph Node Metastases as Index Lesion in (68)Ga-PSMA-PET/CT Imaging for Recurrent Prostate Cancer
por: Leitsmann, Conrad, et al.
Publicado: (2021)

Intermittent Radioligand Therapy with (177)Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
por: Mader, Nicolai, et al.
Publicado: (2023)

(68)Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer
por: Damjanovic, Jonathan, et al.
Publicado: (2019)

Incidental prostate cancer in transurethral resection of prostate specimens in men aged up to 65 years
por: Perera, Marlon, et al.
Publicado: (2016)

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [(18)F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation
por: Shenderov, Eugene, et al.
Publicado: (2017)

Oligometastatic Disease Detection with (68)Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer Patients (HSPC) with Biochemical Recurrence after Radical Prostatectomy: Predictive Factors and Clinical Impact
por: Artigas, Carlos, et al.
Publicado: (2021)

Nodal and osseous oligometastatic prostate cancer: a cohort including the introduction of PSMA-PET/CT-guided stereotactic and hypofractionated radiotherapy with elective nodal therapy
por: Gawish, Ahmed, et al.
Publicado: (2022)

The Continuum of Metastatic Prostate Cancer: Interpreting PSMA PET Findings in Recurrent Prostate Cancer
por: Kase, Adam M., et al.
Publicado: (2022)

Feasibility of biology-guided radiotherapy using PSMA-PET to boost to dominant intraprostatic tumour
por: Gaudreault, Mathieu, et al.
Publicado: (2022)

(68)Ga-PSMA-PET/CT for the evaluation of pulmonary metastases and opacities in patients with prostate cancer
por: Damjanovic, Jonathan, et al.
Publicado: (2018)

PSMA PET in Imaging Prostate Cancer
por: Tsechelidis, Ioannis, et al.
Publicado: (2022)

Comparison of (68)Ga-PSMA PET/CT and (18)F-PSMA PET/CT of a Patient with Prostate Cancer Recurrence on Urinary Bladder Wall
por: Soydal, Çiğdem, et al.
Publicado: (2023)

Globalization of Continuing Professional Development by Journal Clubs via Microblogging: A Systematic Review
por: Roberts, Matthew John, et al.
Publicado: (2015)

Predicting the Risk of Metastases by PSMA-PET/CT—Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma
por: Koerber, Stefan A., et al.
Publicado: (2021)

The value of (68)Ga-PSMA enhanced PET-CT and MR-PET in patients with biochemical recurrent prostate cancer
por: Rummeny, E, et al.
Publicado: (2015)

Hybrid imaging with [(68)Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer
por: Glemser, P. A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kimpujnpn2qqb4udrmedf2qg9v